696 related articles for article (PubMed ID: 22028261)
1. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
2. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
3. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
4. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
6. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
7. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
9. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
11. ANCA vasculitis: time for a change in treatment paradigm? Not yet.
Ntatsaki E; Mooney J; Watts RA
Rheumatology (Oxford); 2011 Jun; 50(6):1019-24. PubMed ID: 21292735
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment for vasculitis.
Jayne D
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223
[No Abstract] [Full Text] [Related]
13. Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: rituximab may be the right choice?
Szilasi M; Mátyus J; File I; Szücs G; Rákóczi E; Pfliegler G; Szabó Z; Végh E; Szekanecz Z
Autoimmunity; 2012 Jun; 45(4):304-9. PubMed ID: 22443800
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
Guerry MJ; Brogan P; Bruce IN; D'Cruz DP; Harper L; Luqmani R; Pusey CD; Salama AD; Scott DG; Savage CO; Watts RA; Jayne DR
Rheumatology (Oxford); 2012 Apr; 51(4):634-43. PubMed ID: 21613248
[TBL] [Abstract][Full Text] [Related]
15. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
Jayne D
Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
[No Abstract] [Full Text] [Related]
16. Rituximab in ANCA-associated vasculitis: fad or fact?
Fervenza FC
Nephron Clin Pract; 2011; 118(2):c182-8; discussion c188. PubMed ID: 21160229
[TBL] [Abstract][Full Text] [Related]
17. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
Pendergraft WF; Cortazar FB; Wenger J; Murphy AP; Rhee EP; Laliberte KA; Niles JL
Clin J Am Soc Nephrol; 2014 Apr; 9(4):736-44. PubMed ID: 24626432
[TBL] [Abstract][Full Text] [Related]
18. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
20. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
Rutgers A; Kallenberg CG
Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
